WO2009040849A1 - Utilisation de l'acide aminé l-kynurénine et de ses dérivés pour le traitement de pathologies inflammatoires chroniques - Google Patents
Utilisation de l'acide aminé l-kynurénine et de ses dérivés pour le traitement de pathologies inflammatoires chroniques Download PDFInfo
- Publication number
- WO2009040849A1 WO2009040849A1 PCT/IT2008/000553 IT2008000553W WO2009040849A1 WO 2009040849 A1 WO2009040849 A1 WO 2009040849A1 IT 2008000553 W IT2008000553 W IT 2008000553W WO 2009040849 A1 WO2009040849 A1 WO 2009040849A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- derivatives
- kynurenine
- acid
- chronic inflammatory
- allergy
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 29
- 230000002757 inflammatory effect Effects 0.000 title claims abstract description 23
- 230000001684 chronic effect Effects 0.000 title claims abstract description 22
- 230000007170 pathology Effects 0.000 title claims abstract description 21
- 150000001413 amino acids Chemical class 0.000 title description 3
- YGPSJZOEDVAXAB-UHFFFAOYSA-N (R)-Kynurenine Natural products OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 claims abstract description 65
- 208000016532 chronic granulomatous disease Diseases 0.000 claims abstract description 41
- 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 claims abstract description 40
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 30
- 230000007815 allergy Effects 0.000 claims abstract description 29
- 150000001412 amines Chemical class 0.000 claims abstract description 14
- -1 L-kynurenine amino acid Chemical class 0.000 claims abstract description 13
- 108010074328 Interferon-gamma Proteins 0.000 claims description 34
- 238000002560 therapeutic procedure Methods 0.000 claims description 23
- 208000026935 allergic disease Diseases 0.000 claims description 22
- VCKPUUFAIGNJHC-UHFFFAOYSA-N 3-hydroxykynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC(O)=C1N VCKPUUFAIGNJHC-UHFFFAOYSA-N 0.000 claims description 16
- 102000008070 Interferon-gamma Human genes 0.000 claims description 16
- 229940044627 gamma-interferon Drugs 0.000 claims description 15
- WJXSWCUQABXPFS-UHFFFAOYSA-N 3-hydroxyanthranilic acid Chemical compound NC1=C(O)C=CC=C1C(O)=O WJXSWCUQABXPFS-UHFFFAOYSA-N 0.000 claims description 14
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 12
- 208000006673 asthma Diseases 0.000 claims description 10
- 201000009961 allergic asthma Diseases 0.000 claims description 9
- GJAWHXHKYYXBSV-UHFFFAOYSA-N quinolinic acid Chemical compound OC(=O)C1=CC=CN=C1C(O)=O GJAWHXHKYYXBSV-UHFFFAOYSA-N 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- 239000013566 allergen Substances 0.000 description 20
- 102100037850 Interferon gamma Human genes 0.000 description 18
- 208000010668 atopic eczema Diseases 0.000 description 12
- 230000000172 allergic effect Effects 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 210000000987 immune system Anatomy 0.000 description 7
- 239000000969 carrier Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000009169 immunotherapy Methods 0.000 description 6
- 210000000440 neutrophil Anatomy 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 241001225321 Aspergillus fumigatus Species 0.000 description 5
- 241000233866 Fungi Species 0.000 description 5
- 230000000843 anti-fungal effect Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 210000001539 phagocyte Anatomy 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 description 4
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
- 102000015728 Mucins Human genes 0.000 description 4
- 108010063954 Mucins Proteins 0.000 description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 description 4
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000003979 eosinophil Anatomy 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 229960002591 hydroxyproline Drugs 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 4
- 229920002101 Chitin Polymers 0.000 description 3
- YGPSJZOEDVAXAB-QMMMGPOBSA-N L-kynurenine Chemical class OC(=O)[C@@H](N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-QMMMGPOBSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010002199 Anaphylactic shock Diseases 0.000 description 2
- 241000228212 Aspergillus Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 206010018691 Granuloma Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 230000009285 allergic inflammation Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 239000010437 gem Substances 0.000 description 2
- 229910001751 gemstone Inorganic materials 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000003641 microbiacidal effect Effects 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 241000238876 Acari Species 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102100039121 Histone-lysine N-methyltransferase MECOM Human genes 0.000 description 1
- 102100024594 Histone-lysine N-methyltransferase PRDM16 Human genes 0.000 description 1
- 101001033728 Homo sapiens Histone-lysine N-methyltransferase MECOM Proteins 0.000 description 1
- 101000686942 Homo sapiens Histone-lysine N-methyltransferase PRDM16 Proteins 0.000 description 1
- 101000654718 Homo sapiens SET-binding protein Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 102100032741 SET-binding protein Human genes 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 208000037114 Symptom Flare Up Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027024 X-linked chronic granulomatous disease Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000036733 chronic X-linked granulomatous disease Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 230000035874 hyperreactivity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 201000009085 invasive aspergillosis Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000005111 ocular hyperemia Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000003793 prenatal diagnosis Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000006941 response to substance Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000012154 short term therapy Methods 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Definitions
- the present invention concerns the use of the L-kynurenine amino acid and derivatives thereof for the treatment of chronic inflammatory pathologies. More particularly, the invention refers to the use of the L-kynurenine amino acid and derivatives thereof for the treatment of chronic inflammatory pathologies like, for example, chronic granulomatous disease (CGD) and allergies.
- Chronic granulomatous disease (CGD) is a pathology affecting phagocytes, white blood cells "scavengers" attacking and incorporating dead microorganisms and cells.
- phagocytes are unable in killing some types of microorganisms: phagocytes normally move towards organism areas wherein an infection occurs, but are unable to carry out a reaction cascade resulting in microorganism "digestion". Due to this deficit, CGD affected patients are extremely susceptible to serious infections from bacteria and fungi (1).
- infections can affect various tissues and organs: pneumonias, liver, spleen and lymphonode enlargement. Frequently the disease results in the development of granulomas (inflammatory tissues masses), which can occur in any part of the body. More often granulomas occur in skin, lungs, lymphonodes, liver or bone and, occasionally, they can block digesting or urinary tract.
- CGD is inherited as chromosome X- linked recessive form. Only males are susceptible to this disease form, while females are healthy carriers (2).
- An healthy carrier mother will have 25 % probability to conceive an affected male, 25 % probability for an healthy carrier daughter, 50 % probability for male or female healthy and not carrier.
- a recessive autosomic inheritance occurs and, in this case, the disease indifferently affects males and females: an affected child can only be born if both parents are healthy carriers of the genetic modification.
- An pair of healthy carriers will have 25% of possibility, at every pregnancy, to conceive an affected son or daughter, 50% of possibility to have an healthy son or daughter carriers, 25% of possibility for an healthy son or daughter and not carriers (3).
- the healthy carriers can be identified with specific tests on a blood withdrawal.
- the disease generating mutation i.e. the genetic error
- DNA analysis it is possible to carry out the prenatal diagnosis; the possibility must carefully be evaluated at specialized Centres before the pregnancy onset.
- CGD is a very serious disease and until some years ago affected persons had insufficient survival possibilities.
- a therapy often resulting in successful results is based on gamma-interferon, a substance stimulating the immune system and limiting the occurrence of infections (5).
- the bone marrow transplant can be used in order to recover from the disease definitively (6).
- the present invention concerns the use of L-kynurenine amino acid and derivatives thereof for the treatment of chronic inflammatory pathologies.
- chronic inflammatory pathologies there are allergies too.
- Allergies are an excessive response to substances that generally are not dangerous for humans, representing parossistic immune response in comparison to normal.
- immune system protects humans against pathogenic organisms, like bacteria, viruses or toxic substances.
- the allergy is the response that an hyper-sensible immune system directs towards not pathogenic organisms. It is the first allergen exposure that provokes the individual allergic reaction and it results in that the same recognises allergen at every contact later on.
- the symptoms occur at the second and subsequent exposures and are strictly dependent not only on the involved allergen in issue, but also on involved body portion and immune response intensity.
- the allergen comes into contact with the individual immune system, it stimulates the antibody production, which bind to histamine containing cells. It is the production of this substance that results, for allergic patient, in typical symptoms generation: pruritus, affected tissue swelling, mucus hyper-secretion, muscular spasms.
- the gravity and multiplicity of these symptoms are strongly subjective being variable depending on affected patient.
- the more common allergens are food, drugs, various cosmetic contained compounds, various jewel or costume jewel contained metals bug punctures, dust mites, pollens and mildews, domestic animals.
- Symptoms can vary as to intensity and typology depending on the response, involved body portion and patient immune system sensitivity. In general terms, however, some symptoms are common: rhinitis, cough, respiration difficulties, increased tearing, pruritus at contact zone (eyes, nose, throat, skin), cutaneous rash, vomit, diarrhoea, headache can occur.
- the allergen is a drug or food
- the or elimination test the suspected substance is respectively suspended or introduced in the patient therapy (in the case of drug) or diet (in the case of food) waiting for a reduction or exacerbation of the immune response.
- high levels of antibodies and immunoglobulin (particularly IgE) or eosinophil increase indicate that the immune system already has come in contact with the allergen.
- the therapies against allergies usually comprise, respectively, a short term therapy, aiming the elimination of the immediate symptoms, and a long term therapy, aiming the prevention of future allergic crises.
- the allergies are treated with antihistaminic drugs, succeeding to alleviate light and moderated symptoms but, unfortunately, resulting in sleepiness, therefore the same are not appropriate when the patients are involved in managing potentially dangerous equipments, or driving, or whichever other situation wherein the attention is an essential requirement.
- the nasal congestion it is advisable to use decongestant products, even if care is to be taken when these sprays are chronically used, because it can result in addiction.
- the contact with the allergen in any case avoiding the contact with the allergen by far remains the better treatment for allergy (mainly where alimentary or pharmacological allergies are involved).
- the allergic diseases result from the induction of helper (Th) 2 T-cells and IgE specific responses for the environmental common antigens (allergens) in susceptible individuals.
- Th helper
- IgE regulatory T-cell populations
- Treg can actively prevent Th2 responses to allergens occurring in not-atopic individuals and function thereof can be weakened in allergic patients.
- the therapies can act by means of modulation of Treg function.
- Current searches aim the understanding of the mechanisms involved in the generation and function of allergen-specific Tregs.
- a primary object is to promote the development of therapeutic regimes aiming the induction of inhibitory allergen-specific but at the same time long-lasting and localised mechanisms.
- the immunotherapy consists of several injections over the time containing increasing doses of response triggering allergen in order that the organism is desensitised with respect to involved substance. Subcutaneous injections containing various allergen concentrations resulting in IgE decrease and IgG increase are carried out. Many patients took advantage of this type of treatment, and some thereof experienced a decrease of the allergy symptoms already one year after the therapy initiation. Usually immunotherapy is suspended after 3 years; although on one hand some patients have experienced good results also after the treatment suspension, on the other there are others which have showed a symptom worsening. In the most cases, however, immunotherapy has revealed an effective therapy for the treatment of allergic rhinitis, asthma and insect bites.
- the allergic persons substantially consists of two large classes: one comprises people experimenting only annoying disturbs resulting from allergy (rhinitis, eye redness, mucus hypersecretion,...) and another comprises people unfortunately life threatening when contact the allergen, i.e. are subjected to the usually named anaphylactic shock. Most allergies are treated timely and successfully, but only as far as the current crisis; a later contact with the allergen will trigger another crisis anyway.
- the desensitisation of the immune system resulting from immunotherapy can optimally prevent future allergic crises, but it is to be considered that injections can provoke cutaneous rash or, in some subjects, also anaphylactic shock.
- this method can be only used for some allergens, like pollens, dust and similar ones, but not, as an example, for food allergies. It is also true anyway that the immunotherapy is proved to be effective in 2/3 cases, although a long term treatment is required.
- the authors of the present invention have been studied new therapeutic approaches aiming the control of chronic inflammatory condition accompanying the allergic condition.
- the attention has been focused on the immunological component controlling the inflammation and limiting the harmful effects thereof.
- the authors of the present invention have demonstrated that by means of the treatment with exogenous kynurenine and gamma-interferon the allergic inflammatory symptoms are ameliorated.
- L- kynurenine amino acid and derivatives thereof both natural, for example 3-hydroxykynurenine, anthranijic acid, 3-hydroxyanthranilic acid, quinolinic acid, and synthetic for use in medical field.
- the present invention concerns moreover a pharmaceutical composition
- a pharmaceutical composition comprising or consisting of L-kynurenine amino acid and/or derivatives thereof, both natural, for example 3-hydroxykynurenine, anthranilic acid, 3-hydroxyanthranilic acid, quinolinic acid, and synthetic, possibly in combination with gamma-interferon, as active principle(s) in association with one or more pharmaceutically acceptable adjuvant and/or excipient.
- These compositions can be advantageously used for the preparation of a medicament for the treatment of chronic inflammatory pathologies like, as an example, the chronic granulomatous disease and allergy, for example, allergic asthma.
- the present invention therefore comprises also the use of the L-kynurenine amino acid and/or its it derivatives both natural, as for example 3-hydroxykynurenine, anthranilic acid, 3-hydrixyantranilic acid, quinolinic acid, and synthetic, eventually in combination with gamma- interferon, for the preparation of a medicament for the treatment of chronic inflammatory pathologies as, as for example, chronic granulomatous disease and allergy, as for example, allergic asthma.
- L-kynurenine amino acid and/or derivatives thereof both natural, for example 3-hydroxykynurenine, anthranilic acid, 3-hydroxyanthranilic acid, quinolinic acid, and synthetic, and ⁇ -interferon.
- the invention concerns said combination for simultaneous, separated or sequential use in the therapy of chronic inflammatory pathologies like, for example, the chronic granulomatous disease and allergy, for example, allergic asthma. Therefore, the use of combination, as above defined, for the preparation of a medicament for the treatment of chronic inflammatory pathologies like, for example, chronic granulomatous disease and allergy, for example, allergic asthma, is a further object of the present invention.
- FIG 1 shows that L-kynurenine is the first product of tryptophan metabolic degradation by an enzyme known as IDO. In CGD affected patients, this reaction does not occur due to the absence of "superoxide” cofactor.
- Figure 2 shows the decrease of allergic parameters inflammation as the local production of hydroxyproline, mucin and IgE antibodies as a result of the treatment with kynurenine (L-kyn) and ⁇ interferon in comparison to treatment with placebo, kynurenine or ⁇ -interferon.
- Figure 3 shows the decrease of eosinophils occurring in BAL as a result of the treatment with kynurenine (L-kyn) and ⁇ -interferon in comparison to treatment with placebo, kynurenine or ⁇ -interferon.
- Example 1 Study on the effectiveness of the substitution therapy with exogenous kynurenine in CGD mouse
- CGD mouse display an increased susceptibility to the pulmonary infection by Aspergillus fumigatus fungus, such that their intratracheal fungus colonization leads unavoidably to a lethal form of invasive aspergillosis. Therefore the working hypothesis has been that the correction of the metabolic defect (not production endogenous kynurenine) could be corrected by means of substitution therapy with exogenous kynurenine (i.e. synthetic, completely similar to natural one lacking in CGD mouse).
- exogenous kynurenine has been administered to these animals, alone or in combination with ⁇ -interferon (IFN- ⁇ which promotes further metabolism thereof according to reaction scheme as shown in Fig. 1 , and the pharmacokinetic profile of exogenous kynurenine as well as the possible protection against a challenge otherwise lethal with A. fumigatus have been monitored.
- Table 1 shows the kynurenine metabolism and survival of L-kynurenine treated mouse when infected with A. fumigatus.
- CGD and healthy control mouse received subcutaneous implants with placebo or kynurenine (indicated as L-KYN) at day - 1 , and all the groups were infected intratracheally with A. fumigatus (5 x 10 6 ) at day 0.
- Groups of L-KYN treated mouse received also IFN- ⁇ by subcutaneous way at day 1, 3 and 5 (20000 U/mice daily).
- This second experimental model demonstrates that the restored infection resistance in CGD mouse by means of combination treatment with kynurenine and interferon substantially results from a restored microbicidal activity of those cells that, as above reported, characterise CGDI as a phagocyte affecting pathology, white blood cell "scavengers" attacking and incorporating microorganisms.
- Example 3 Study on the effectiveness of the substitution therapy with exogenous kynurenine in ABPA expehmental model
- L-KYN placebo or kynurenine
- Total IgE in serum samples has been measured by means of immunoenzymatic assay (9).
- Results clearly show a drastic reduction of the allergic inflammation parameters like local production of hydroxyproline and mucin as well as IgE antibodies (Figure 2) following the treatment with kynurenine and IFN- ⁇ .
- Cienfuegos V. Hernandez-Bautista, and F. Espinosa-Rosales. 2006.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne l'utilisation de l'acide aminé L-kynurénine et de ses dérivés, à la fois naturels et synthétiques, pour le traitement de pathologies inflammatoires chroniques comme, par exemple, une granulomatose chronique familiale (CGD) et des allergies.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITRM2007A000447 | 2007-08-21 | ||
IT000447A ITRM20070447A1 (it) | 2007-08-21 | 2007-08-21 | Uso dell'amminoacido l-chinurenina e dei suoi derivati per il trattamento delle patologie infiammatorie croniche. |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009040849A1 true WO2009040849A1 (fr) | 2009-04-02 |
Family
ID=40299904
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IT2008/000553 WO2009040849A1 (fr) | 2007-08-21 | 2008-08-21 | Utilisation de l'acide aminé l-kynurénine et de ses dérivés pour le traitement de pathologies inflammatoires chroniques |
Country Status (2)
Country | Link |
---|---|
IT (1) | ITRM20070447A1 (fr) |
WO (1) | WO2009040849A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018044724A1 (fr) * | 2016-08-31 | 2018-03-08 | Ampio Pharmaceuticals, Inc. | Traitement d'une maladie avec de la n-acétyl-kynurénine |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1369114A1 (fr) * | 2002-06-07 | 2003-12-10 | Peter Priv. Doz. Dr. Terness | Utilisation de métabolites du tryptophane comme agents pharmaceutiques |
-
2007
- 2007-08-21 IT IT000447A patent/ITRM20070447A1/it unknown
-
2008
- 2008-08-21 WO PCT/IT2008/000553 patent/WO2009040849A1/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1369114A1 (fr) * | 2002-06-07 | 2003-12-10 | Peter Priv. Doz. Dr. Terness | Utilisation de métabolites du tryptophane comme agents pharmaceutiques |
Non-Patent Citations (2)
Title |
---|
HEYLIGER S O ET AL: "The anti-inflammatory effects of quinolinic acid in the rat", LIFE SCIENCES, vol. 64, no. 14, 26 February 1999 (1999-02-26), pages 1177 - 1187, XP002515837, ISSN: 0024-3205 * |
ROMANI LUIGINA ET AL: "Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease", NATURE (LONDON), vol. 451, no. 7175, January 2008 (2008-01-01), pages 211, XP002515838, ISSN: 0028-0836 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018044724A1 (fr) * | 2016-08-31 | 2018-03-08 | Ampio Pharmaceuticals, Inc. | Traitement d'une maladie avec de la n-acétyl-kynurénine |
US11478441B2 (en) | 2016-08-31 | 2022-10-25 | Ampio Pharmaceuticals, Inc. | Treatment of disease with n-acetyl kynurenine |
Also Published As
Publication number | Publication date |
---|---|
ITRM20070447A1 (it) | 2009-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11344545B2 (en) | Use of levocetirizine and montelukast in the treatment of autoimmune disorders | |
Lappin et al. | Effect of oral administration of cyclosporine on Toxoplasma gondii infection status of cats | |
Zhang et al. | PD-1 deficiency promotes macrophage activation and T-helper cell type 1/T-helper cell type 17 response in pneumocystis pneumonia | |
TWI393569B (zh) | 供治療真菌感染(特別是曲霉病)並包含ptx3和抗真菌劑之藥劑 | |
Wang et al. | NOD2 regulates microglial inflammation through the TAK1-NF-κB pathway and autophagy activation in murine pneumococcal meningitis | |
Ma et al. | Oral administration of allergen extracts from mugwort pollen desensitizes specific allergen-induced allergy in mice | |
Hanh et al. | Evidence for asthma in the lungs of mice inoculated with different doses of Toxocara canis | |
Gbotosho et al. | Plasmodium falciparum hyperparasitaemia in Nigerian children: epidemiology, clinical characteristics, and therapeutic responses to oral artemisinin-based combination treatments | |
WO2009040849A1 (fr) | Utilisation de l'acide aminé l-kynurénine et de ses dérivés pour le traitement de pathologies inflammatoires chroniques | |
Wang et al. | Analysis of pathogenetic process of fungal rhinosinusitis: Report of two cases | |
Grisolia et al. | Itraconazole and neutrophil interactions in the immune-inflammatory response of paracoccidioidomycosis using a murine air pouch infection model | |
Kirtsreesakul et al. | Desloratadine partially inhibits the augmented bacterial responses in the sinuses of allergic and infected mice | |
US20220119819A1 (en) | Formulation | |
CN114569559B (zh) | 乌灵菌粉的新用途 | |
Chumpitazi et al. | Contribution of anti-Hsp70. 1 IgG antibody levels to the diagnostic certainty of clinically suspected ocular toxoplasmosis | |
KR20190090271A (ko) | 알레르기비염 완화, 치료 또는 예방용 약학조성물 | |
Ramezaninejad et al. | The Efficacy and Safety of Adding Chlorpromazine to Atazanavir/Ritonavir Regimen in the Treatment of Moderate COVID-19 Patients, a Randomized Double-blind Clinical Trial | |
Thangaraju et al. | Eosinophilia as an adverse drug reaction secondary to thalidomide therapy in Lepra type 2 reactions: a mandate responsibility | |
Maffezzoni et al. | Efficacy of oral intake of a compound medical device in the treatment of laryngopharyngeal reflux disease: a clinical investigation and nasal cytological correlations | |
JP2010507649A (ja) | アレルギーの予防及び治療のための医薬を調製するためにサイモシンアルファ1の使用 | |
Copley et al. | OC52 Trientine is a safe and effective treatment for Wilson’s disease | |
Tom et al. | Eczematous disorders | |
Dimitrova et al. | Studies on the therapeutic effect of flucloxacillin in dogs with experimental staphylococcal infection in the skin and soft tissues | |
Machado et al. | Effects of dexamethasone, cyclosporine and betamethasone on inflammatory cell recruitment in mice infected with Strongyloides venezuelensis | |
Freye et al. | ATC Malachlorite® for treatment of patients with acute Plasmodium falciparum infection: A pilot study incorporating 500 patients in the rural area of Cameroon |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08833880 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08833880 Country of ref document: EP Kind code of ref document: A1 |